Trial Profile

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alnuctamab (Primary) ; Dexamethasone (Primary) ; Mezigdomide (Primary)
Indications Multiple myeloma
Focus Adverse reactions; Therapeutic Use
Sponsors Celgene Corporation

04 Apr 2025 Planned End Date changed from 29 Aug 2025 to 30 May 2025.
21 Oct 2024 Planned primary completion date changed from 29 Aug 2025 to 30 May 2025.
21 Aug 2024 Planned End Date changed from 13 Feb 2032 to 29 Aug 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com